biostudies-literatureUnknown14Allen-Philbey K<h4>Objective</h4>To report on safety and effectiveness of subcutaneous cladribine (Litak^®) in multiple sclerosis (MS) patients.<h4>Methods</h4>Litak^® was offered to MS-patients irrespective of disease course. Litak^® 10 mg was administered for 3-4 days during week 1. Based on lymphocyte count at week 4, patients received another 0-3 doses at week 5. A second course was administered 11 months later. Follow-up included adverse events, relapses, expanded disability status scale (EDSS), 9-hole-peg and Timed-25-foot-walking tests, no-evidence-of-disease-activity (NEDA), no-evidence-of-progression-or-active-disease (NEPAD), MRI, cerebrospinal fluid (CSF) neurofilament light chain (NfL), and lymphocyte counts.<h4>Results</h4>In all, 208 patients received at least Therapeutic advances in neurological disorders17562864211057661https://www.ebi.ac.uk/biostudies/studies/S-EPMC8842147biostudies-literatureSubcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.PMC8842147Giovannoni GConstantinescu CSMattoscio MPavitt SMacDougall AGran BFord HDalton CBaker DBlain CStennett AWebb SJuliusson GMarta MSharrack BMao ZKhaleeli ZPeruzzotti-Jametti LAlvarez-Gonzalez CChapman CAdams ABianchi LChung KFarrell RADe Trane SFisniku LZhou XSchmierer KSilber ETurner BPMathews JScalfari ATallantyre ECGnanapavan SYildiz OHobart JPearson OAllen-Philbey KfalseSubcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.<h4>Objective</h4>To report on safety and effectiveness of subcutaneous cladribine (Litak^®) in multiple sclerosis (MS) patients.<h4>Methods</h4>Litak^® was offered to MS-patients irrespective of disease course. Litak^® 10 mg was administered for 3-4 days during week 1. Based on lymphocyte count at week 4, patients received another 0-3 doses at week 5. A second course was administered 11 months later. Follow-up included adverse events, relapses, expanded disability status scale (EDSS), 9-hole-peg and Timed-25-foot-walking tests, no-evidence-of-disease-activity (NEDA), no-evidence-of-progression-or-active-disease (NEPAD), MRI, cerebrospinal fluid (CSF) neurofilament light chain (NfL), and lymphocyte counts.<h4>Results</h4>In all, 208 patients received at least 2021-01-01T00:00:00Z20212025-06-01T02:33:10.949Z2025-06-01T02:33:10.949ZS-EPMC88421473517380810.1177/17562864211057661